EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #05761_C
无血清，用于人神经干细胞和祖细胞的扩增培养
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
-
Heparin SolutionCell culture supplement
-
Human Recombinant bFGFBasic fibroblast growth factor
-
Human Recombinant EGFEpidermal growth factor
总览
NeuroCult™-XF 扩增培养基是一种标准化的无异种成分、无血清的培养基，适用于来源于正常组织或肿瘤样本的人神经干细胞/祖细胞在神经球或贴壁单层培养系统中进行体外培养。在添加适当的细胞因子后，该培养基经过优化，可长期维持人神经干细胞的体外培养状态，同时保持其自我更新、增殖及分化潜能。
注意：配制完全的培养体系时需添加无载体人重组 EGF（产品号 #78006）和人重组 bFGF（产品号 #78003）。可选添加肝素（产品号 #07980），但需注意肝素溶液含有非人源动物成分，如需构建完全无异种成分体系，则可省略肝素的添加。
注意：配制完全的培养体系时需添加无载体人重组 EGF（产品号 #78006）和人重组 bFGF（产品号 #78003）。可选添加肝素（产品号 #07980），但需注意肝素溶液含有非人源动物成分，如需构建完全无异种成分体系，则可省略肝素的添加。
注意：配制完全的培养体系时需添加无载体人重组 EGF（产品号 #78006）和人重组 bFGF（产品号 #78003）。可选添加肝素（产品号 #07980），但需注意肝素溶液含有非人源动物成分，如需构建完全无异种成分体系，则可省略肝素的添加。
注意：配制完全的培养体系时需添加无载体人重组 EGF（产品号 #78006）和人重组 bFGF（产品号 #78003）。可选添加肝素（产品号 #07980），但需注意肝素溶液含有非人源动物成分，如需构建完全无异种成分体系，则可省略肝素的添加。
亚型
专用培养基
细胞类型
脑肿瘤干细胞，神经干/祖细胞
种属
人
应用
细胞培养，克隆筛选，扩增，功能学筛选，球状体培养
品牌
NeuroCult
研究领域
癌症，疾病建模，药物发现和毒理检测，神经科学，干细胞生物学，移植研究
制剂类别
无血清，Xeno-Free
实验数据
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (11)
文献 (3)
The Use of Autologous Mesenchymal Stem Cells for Cell Therapy of Patients with Amyotrophic Lateral Sclerosis in Belarus. Bulletin of experimental biology and medicine 2015 AUG
Abstract
We studied a new method of treatment of amyotrophic lateral sclerosis with autologous mesenchymal stem cells. Autologous mesenchymal stem cells were injected intravenously (intact cells) or via lumbar puncture (cells committed to neuronal differentiation). Evaluation of the results of cell therapy after 12-month follow-up revealed slowing down of the disease progression in 10 patients in comparison with the control group consisting of 15 patients. The cell therapy was safe for the patients.
Chemically defined serum-free and xeno-free media for multiple cell lineages. Annals of translational medicine 2014 OCT
Abstract
Cell culture is one of the most common methods used to recapitulate a human disease environment in a laboratory setting. Cell culture techniques are used to grow and maintain cells of various types including those derived from primary tissues, such as stem cells and cancer tumors. However, a major confounding factor with cell culture is the use of serum and animal (xeno) products in the media. The addition of animal products introduces batch and lot variations that lead to experimental variability, confounds studies with therapeutic outcomes for cultured cells, and represents a major cost associated with cell culture. Here we report a commercially available serum-free, albumin-free, and xeno free (XF) media (Neuro-Pure(TM)) that is more cost-effective than other commercial medias. Neuro-Pure was used to maintain and differentiate various cells of neuronal lineages, fibroblasts, as well as specific cancer cell lines; without the use of contaminants such serum, albumin, and animal products. Neuro-Pure allows for a controlled and reproducible cell culture environment that is applicable to translational medicine and general tissue culture.
Hypoxia induces a phase transition within a kinase signaling network in cancer cells Proceedings of the National Academy of Sciences 2013 APR
Abstract
Hypoxia is a near-universal feature of cancer, promoting glycolysis, cellular proliferation, and angiogenesis. The molecular mechanisms of hypoxic signaling have been intensively studied, but the impact of changes in oxygen partial pressure (pO2) on the state of signaling networks is less clear. In a glioblastoma multiforme (GBM) cancer cell model, we examined the response of signaling networks to targeted pathway inhibition between 21% and 1% pO2. We used a microchip technology that facilitates quantification of a panel of functional proteins from statistical numbers of single cells. We find that near 1.5% pO2, the signaling network associated with mammalian target of rapamycin (mTOR) complex 1 (mTORC1)--a critical component of hypoxic signaling and a compelling cancer drug target--is deregulated in a manner such that it will be unresponsive to mTOR kinase inhibitors near 1.5% pO2, but will respond at higher or lower pO2 values. These predictions were validated through experiments on bulk GBM cell line cultures and on neurosphere cultures of a human-origin GBM xenograft tumor. We attempt to understand this behavior through the use of a quantitative version of Le Chatelier's principle, as well as through a steady-state kinetic model of protein interactions, both of which indicate that hypoxia can influence mTORC1 signaling as a switch. The Le Chatelier approach also indicates that this switch may be thought of as a type of phase transition. Our analysis indicates that certain biologically complex cell behaviors may be understood using fundamental, thermodynamics-motivated principles.
更多信息
| 种属 | Human |
|---|---|
| 配方类别 | Serum-Free, Xeno-Free |
相关产品
-
NeuroCult™ NS-A 基础培养基（人）培养人神经干细胞和祖细胞的基础培养基
-
NeuroCult™ NS-A 扩增试剂盒（人）培养人神经干细胞和祖细胞的培养基
-
NeuroCult™ NS-A 分化试剂盒（人）人神经干细胞和祖细胞分化的培养基
法律声明:
Sold under license from StemCells California, Inc. US Patent Nos. 5,750,376; 5,851,832; 5,980,885; 5,968,829; 5,981,165; 6,071,889; 6,093,531; 6,103,530; 6,165,783; 6,238,922. 质量保证:
产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
Sold under license from StemCells California, Inc. US Patent Nos. 5,750,376; 5,851,832; 5,980,885; 5,968,829; 5,981,165; 6,071,889; 6,093,531; 6,103,530; 6,165,783; 6,238,922. 质量保证:
产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
